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Background: To determine factors associated with outcomes and microvascular invasion (MVI) in
patients undergoing liver transplantation (LT) for hepatocellular carcinoma (HCC).
Methods: Between July 1996 and August 2008 at the Universities of Kentucky or Tennessee, LT
recipients were retrospectively analysed.
Results: One hundred and one patients had HCC in the explanted liver; one patient was excluded
because of fibrolamellar histology. Seventy-nine (79%) were male and 81 (81%) were older than 50. HCC
was incidental in 32 patients (32%). Median follow-up was 31 months. Ten patients (10%) developed
recurrence, which was associated with poor survival (P = 0.006). Overall 1-, 3-, and 5-year survival rates
were 87%, 69% and 62%, respectively. Excluding patients with lymph node metastasis (LNM) or MVI
yielded 91%, 81% and 75% survival at the same time points. MVI was independently associated with
recurrence (OR 28.40, 95% CI 1.77–456.48, P = 0.018) and decreased survival (OR 4.70, 95% CI
1.24–17.80, P = 0.023), and LNM with decreased survival (OR 6.05, 95% CI 1.23–29.71, P = 0.027).
Tumour size (OR 4.1, 95% CI 1.2–13.5, P = 0.013) and alpha-fetoproptein (AFP) > 100 (OR 5.0, 95% CI
1.4–18.1, P = 0.006) were associated with MVI.
Conclusions: MVI greatly increases the risk of recurrence and death after LT for HCC, and is strongly
associated with tumour size and AFP > 100.
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Introduction
Hepatocellular carcinoma (HCC) is the most common primary
malignancy of the liver and represents the third leading cause of
cancer-related deaths worldwide.1 Although many patients are
candidates for surgical resection, liver transplantation (LT) is the
preferred treatment for HCC as it offers not only removal of the
primary lesion and any additional tumour foci but also treatment
for the concomitant cirrhosis that is the setting for many HCC
cases. Early experience with LT in non-selected HCC patients
yielded high death rates from recurrent disease.2,3 In light of per-
petual organ shortage, these results called into question the justi-
fication of LT to treat HCC. Later experience, however, showed
that patients with HCC, if carefully selected on the basis of
tumour size and number, could fare as well after LT as patients
transplanted for other indications.4–6 Rate of tumour recurrence is
much lower after LT than surgical resection7–9 but is still the major
limitation for long-term survival.
Besides tumour recurrence, several other factors have been
associated with decreased patient survival after LT for HCC in
previous studies, namelymicrovascular invasion (MVI), histologi-
cal grade, tumour size and elevated alpha-fetoprotein (AFP).10,11
In these studies, tumour size has been reported to be associated
with MVI, but the relationship between AFP andMVI is less clear.
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AsMVI is most consistently shown to affect survival, we wanted to
evaluate outcomes of patients from two centres who underwent
LT for HCC and determine factors associated with MVI in this
patient population.
Materials and methods
Records of all patients who received LT at the University of Ten-
nessee and University of Kentucky transplant centres between
January 1996 and August 2008 were reviewed. Data obtained
included demographic, clinical (ascites, encephalopathy, variceal
bleeding and jaundice) and laboratory values [bilirubin, pro-
thrombin time and partial thromboplastin time, albumin, blood
urea nitrogen (BUN), creatinine and AFP], time on the transplant
waiting list, tumour characteristics (size, number, cellular differ-
entiation, capsular or vascular invasion and known vs. incidental
presentation), aetiology of cirrhosis, hospital length of stay, adju-
vant treatment, presence of recurrence, characteristics of recur-
rence (site and time) and survival. Histological classification was
according to the tumour-node-metastasis (TNM) and Interna-
tional Union Against Cancer (UICC) systems, performed on
explanted livers by the interpreting pathologist.
For all patients, post-transplant immunosuppression consisted
of a combination of tacrolimus or cyclosporine, mycophenolate
mofetil (MMF) and steroids. MMF therapy was typically discon-
tinued at 6 months and steroids rapidly tapered; beyond 1 year,
most patients were maintained on monotherapy with either tac-
rolimus or cyclosporine. Bridging therapy such as transarterial
chemoembolization (TACE), radiofrequency ablation (RFA) or
percutaneous ethanol injection (PEI) was used in patients with
large, rapidly growing lesions or those with a long anticipated
waiting time, at the discretion of the evaluating surgeon or hepa-
tologist. Post-transplant surveillance consisted of AFP levels and
triphasic computed tomography (CT) imaging every 3–6 months
through the first year, then annually thereafter.
The date of tumour recurrence was defined in one of two ways,
either by observation of newly-increased AFP values along with
subsequent detection of tumour recurrence by imaging (e.g. CT,
ultrasound or chest X-ray) in patients with AFP-positive tumours,
or by the date of positive imaging findings and histological con-
firmation in patients with AFP-negative tumours.
Statistical analysis
Analyses were performed using SPSS version 16 (SPSS Inc.,
Chicago, IL, USA). Overall and disease-free survival rates were
calculated using the Kaplan–Meier method and statistical signifi-
cance defined using the log-rank test. Multivariate analyses for
survival and time to recurrence were performed using Cox pro-
portional hazards model. Fisher’s exact test was used for univari-
ate analysis of dichotomized variables, and logistic regression for
multivariate analysis. Differences were considered significant at
P 0.05 in all cases. Results are expressed as the median or mean
 SD.
Results
Within the study timeframe, a total of 845 LT were performed at
the University of Tennessee and University of Kentucky transplant
centres. Of those, 101 patients had histologically-proven HCC in
the explanted liver. Ninety-eight patients received deceased-donor
organs, whereas three patients received grafts from live donors.
One patient had fibrolamellar histology and was therefore
excluded from analysis. Patient characteristics are reported in
Table 1. End-stage liver disease was attributed to viral infection in
61 patients (61%), including 51 patients with hepatitis C (51%)
and 10 with hepatitis B (10%). Forty-one patients (41%) had
alcohol-related cirrhosis. Bridging therapy (TACE, RFA, PEI, or a
combination thereof) was employed in 13 patients (13%). Twelve
patients (12%) were considered Child–Pugh class A, 41 (41%)
were class B and 47 (47%) were class C; 7 patients (7%) hadmodel
for end-stage liver disease (MELD) scores >15.
Table 2 lists tumour characteristics. In 48 patients (48%), a
single tumour was present. Mean tumour size was 2.6  1.5 cm
(range, 0.7–10 cm). Mean AFP was 195.6  610.0. Thirty-two
patients (32%) had HCC that was found incidentally. There were
30 patients (30%) with MVI invasion. Nineteen patients were
found to have AFP > 100, and 26 patients were found to have
tumours larger than 3 cm. Median follow-up was 31 months
(range, 1–101months); of the 100 patients, 76 (76%) are currently
alive. Four patients (4%) died within 30 days; causes of death were
primary graft non-function, portal vein thrombosis and massive
variceal haemorrhage, sepsis and massive pulmonary embolism.
Wedid not identify a significant difference in patient survival in the
pre- and post-MELD eras (P = 0.141). However, there is a long-
term survival difference in favour of those in the recentMELD era.
Table 1 Patient characteristics
Characteristic No. (%) or
Mean  SD (range)
Male 79 (79)
Age, years 55.7  8.0 (36–72)
Patients with Encephalopathy 49 (49)
Patients with Variceal Bleeding 33 (33)
Patients with Ascites 59 (59)
AFP level (IU) 195.6  610 (1–4560)
Aetiology of cirrhosis:
Hepatitis B 10 (10)
Hepatitis C 51 (51)
Alcohol 41 (41)
Child–Pugh Class:
A 12 (12)
B 41 (41)
C 47 (47)
Follow-up, months Median, 31 (1–101)
Patients alive 76 (76)
AFP, alpha-fetoprotein.
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Causes of later death for the remaining 20 patients are listed in
Table 3. All four patients who were found incidentally to have
lymph node involvement on explant pathology died; two of these
patients died within the first year after LT, one after 18months and
the fourth at 30 months post-LT (causes of death were stroke, liver
failure and two cases of recurrent disease).Overall 1-,3-, and5-year
survival rates were 87%, 69%, and 62%, respectively (Fig. 1).
Excluding those with MVI, respective survival was higher at 92%,
78% and 72% (Fig. 2). Overall disease-free survival at 1, 3, and 5
years was 84%, 67% and 59%, respectively (Fig. 3). Ten patients
subsequently experienced HCC recurrence, the sites of which are
listed in Table 4.Recurrence developedwithin the first year after LT
in four patients, between 1 and 3 years in two patients, and beyond
3 years in four patients.Median time for recurrence was 22months
(range, 4–60months) after LT.Excluding patientswith lymphnode
involvement, MVI yielded impressive survival rates of 91%, 81%,
and 75% at 1, 3, and 5 years, respectively (Table 5).
Analysis of recurrence
Multivariate analysis controlling for age, gender and factors found
on univariate analysis to be predictors of tumour recurrence
(MVI, tumour size and incidental vs. known lesion) showed MVI
to be the only independent factor associated with a higher recur-
rence rate [odds ratio (OR) 28.40, 95% confidence interval (CI)
1.77–456.48, P = 0.018]. Out of those 10 patients with tumour
recurrence, seven had MVI on pathological examination, com-
pared with three without MVI. Tumour recurrence was strongly
associated with poor patient survival in our series (P = 0.006).
Univariate and multivariate analyses of survival
Univariate analysis was performed examining age and gender; the
presence of jaundice, weight loss, ascites, hepatitis B or C, elevated
AFP levels; whether HCC was known or found incidentally;
tumour size, tumor stage, number of lesions, MVI, lymph node
invasion, histological differentiation; post-transplant chemo-
therapy; waiting time andMELD score. Tumour size (greater than
5 cm, P = 0.015), AFP > 100 (P = 0.021), MVI (P = 0.001) and
lymph node metastasis (P < 0.001) were found to be associated
Table 2 Tumour characteristics
Characteristic No. (%) or Mean  SD
(range)
Size, cm 2.6  1.5 (0.7–10 cm)
MVI 30 (30)
Capsular invasion 11 (11)
Poorly-differentiated 19 (19)
Lymph node invasion 4 (4)
Number of tumours
1 48 (48)
2 15 (15)
3 6 (6)
4 27 (27)
Data unavailable 4 (4)
MVI, microvascular invasion.
Table 3 Causes of patient death >30 days after transplantation
Aetiology No. of patients
Tumour recurrence 9
Intracranial haemorrhage 3
Sepsis/multi-organ failure 3
Chronic rejection 2
Portal hypertension 1
Pancreatic cancer 1
Unknown 1
Figure 1 Overall survival in patients undergoing transplantation for
hepatocellular carcinoma
Figure 2 Significant difference in patient survival in the presence of
microvascular invasion
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with poor patient survival. We were unable to show a significant
difference in survival in patients with more than three lesions
compared with other patients within Milan criteria (P = NS).
Multivariate analysis including age, gender and factors identi-
fied as significant on univariate analysis (tumour size, AFP, MVI
and lymph node involvement) demonstrated that MVI and lymph
node metastasis are independently associated with poor survival
in this patient population (MVI, OR 4.70, 95% CI 1.24–17.80,
P = 0.023; lymph node involvement, OR 6.05, 95% CI 1.23–29.71,
P = 0.027).
Factors associated with microvascular invasion on
explanted livers
As MVI is a post-operative finding yet carries strong implications
for outcome, we wanted to identify pre-operative factors that are
associated with MVI. Univariate analysis showed that age (P =
0.050), tumour size greater than 3 cm (P < 0.001), AFP > 100 (P <
0.001) and the presence of multiple lesions (P = 0.004) are asso-
ciated with an increased risk of developing microvascular inva-
sion. Controlling for these factors demonstrated that tumour size
andAFP > 100 are each associated withMVI (tumour size,OR 4.1,
95% CI 1.2–13.5, P = 0.013; elevated AFP, OR 5.0, 95% CI 1.4–
18.1, and P = 0.006). We also repeated the analysis using only
known tumours to determine predictors of MVI. In this subset,
AFP > 100 continued to be an independent variable associated
with MVI (P = 0.034 and OR 4.53). The positive predictive value
(PPV) of large HCC and AFP > 100 for MVI is 88%, and for death
is 55%.
Discussion
Liver transplantation is now a widely accepted therapy for HCC,
particularly when anatomic or functional limitations preclude
resection. In fact, the multifocal nature of these lesions, along with
the common finding of dysplastic nodules, strongly suggest that
total hepatectomy with liver replacement is the best treatment for
HCC in the setting of cirrhosis. Although initial LT results in
non-selected patients with HCC were discouraging, subsequent
series proved that better results could be achieved by employing
defined selection criteria.4–6 The criteria proposed by Mazzaferro
et al.4 in 1996 are used as a basic stratification tool by numerous
transplantation centres worldwide, including the two centres con-
tributing to the present study. Using these Milan criteria, a patient
with a single tumour measuring 5 cm or less, or three or fewer
nodules each smaller than 3 cm, would be a candidate for LT.
Excellent 5-year survival rates of 50–70% or higher have been
achieved when these criteria are followed.12–14 Subsequently, the
University of California at San Francisco reported 57% survival
for patients with HCC who exceeded the Milan criteria but were
within the limits of their expanded criteria, including patients
with solitary lesions less than 6.5 cm in size, or up to three
tumours with the largest no more than 4.5 cm and a combined
tumour diameter of no more than 8 cm.15
Interestingly, a significant portion of our patients had previ-
ously undiagnosed HCC in the explanted liver at the time of LT. In
these patients, current imaging studies (CT and MRI) failed to
demonstrate the presence of malignancy. Although our percent-
age of incidentally found lesions is high, it is also worth noting the
number of patients in our series with small tumours (16 were
1 cm or smaller), which are more difficult to detect using current
imaging protocols. Llovet et al. recently published that only 30%
of such lesions are confirmed by non-invasive criteria.16 This high-
lights the importance of improving staging techniques for patients
with HCC prior to LT, to allow more accurate patient selection.
Tumour recurrence is a major problem after LT, as well as after
resection.7–9 Iwatsuki et al. previously identified bilobar tumour
distribution, size of the greatest lesion and vascular invasion as
strong risk factors for tumour recurrence after LT17. Other strong
Figure 3 Disease-free survival in patients undergoing transplanta-
tion for hepatocellular carcinoma
Table 4 Anatomic sites of tumour recurrence
Site(s) No. of patients
Liver 3
Liver with lung 1
Liver with retroperitoneal lymph nodes 2
Lungs 2
Retroperitoneum 1
Pelvis 1
Table 5 Survival
Time Overall Disease
free
(-) MVI (-) MVI (-) nodal
invasion
1 year 87% 84% 92% 91%
3 years 69% 67% 78% 81%
5 years 62% 59% 72% 75%
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predictors of disease recurrence identified in other studies include
vascular invasion and histopathological grade.5,12 In our series,
patients withMVI were more than 28 times more likely to develop
recurrence. With a median follow-up of 18 months, 10 patients
showed recurrent disease. MVI was also associated with poor sur-
vival using multivariate analysis. This is clearly demonstrated by
the differences in survival between patients with and without
MVI.
Neoadjuvant therapy or bridging intervention (e.g. TACE, RFA
or PEI) is currently recommended by some institutions for
patients awaiting LT. The Barcelona Clinic Liver Cancer Group
published a Markov decision model on the cost-effectiveness of
bridging therapy in this setting, which demonstrated that a patient
expected to wait longer than 6 months for LT would gain quality-
adjusted life years with PEI18 In our series, bridging therapy was
employed in 13 patients, when long waiting times were expected
or in patients with large or rapidly growing lesions. No improve-
ment in survival was seen in this sub-group of patients. Only one
of the seven patients who received RFA subsequently showed
absolutely no remaining cancer in the explanted liver, suggesting
that RFA may work by decreasing tumour burden as previously
proposed.9 At our centres, chemotherapy is currently utilized in
patients with large tumours, or those with capsular or vascular
invasion. However, we did not observe a significant improvement
in survival, in contrast to what has been reported elsewhere.19
Recently, sorafenib, an oral multikinase inhibitor, has been shown
to have a significant impact on survival in patients with advanced
HCC.20 This information suggests the need for new clinical trials
to determine its utility and safety in patients after TACE, ablation,
resection or transplantation.
In our series, all four patients with incidentally found lymph
node metastases died within 30 months, and three out of the four
died within 18 months after LT. Thus, finding lymph node
enlargement at the time of LT presents a dilemma in these
patients. Lymph nodes which are enlarged or otherwise suspicious
in appearance upon exploration should be sampled and sent for
frozen section, in light of the significance of invasion and its
correlation with outcome. Patients without lymph node involve-
ment or MVI experienced 5-year survival in the range of 75%,
demonstrating that excellent results can be achieved in a very
select group of patients. A recent meta-analysis questioned the
impact of lymph node invasion on both recurrence and survival,
and only five studies were found to address this issue directly.21
Considering the impact of having positive lymph nodes on
outcome, and given that enlarged nodes are not uncommonly
found in cirrhotic patients, the meta-analysis concluded that
lymph node sampling could better identify patients with a greater
likelihood of positive outcome.
Other series have determined factors associated with MVI in
patients with HCC undergoing resection.10 Our results show that
MVI and lymph node involvement are associated with decreased
survival, with OR of 4.7 and 6.05, respectively, in agreement with
other studies in patients with HCC undergoing either liver resec-
tion or LT10,22 Because of its prevalence among our patients and its
implications for survival, we sought to determine factors associ-
ated with the presence of MVI. We found that both tumour size
and AFP were strongly related to the presence of MVI on the
explanted liver, in agreement with previous studies.23,24 In our
series, size and AFP > 100 increased the risk of having concurrent
MVI by 4 and 5 times, respectively. Once incidental tumours were
removed from the analysis for predictors of the presence of MVI,
AFP > 100 emerged as an independent factor associated withMVI.
Tumour size has been found to be associated with the presence of
MVI after resection and LT25,26 AFP in conjunction with other
markers such as des-gamma-carboxyprothrombin and AFP-L3
has been associated with tumour burden.27 Other studies using
AFP have identified significance at much higher levels, even 1000
or greater in Pawlik et al.10 We consistently found significance at
much lower AFP thresholds (100 and 200), raising the possibility
that AFP itself is a sensitive predictor of outcome. Interestingly,
the presence of a large HCC and AFP > 100 showed a PPV of 88%
for MVI. However, the PPV of these two variables to predict death
is only 55%, and therefore should not be used to exclude patients
for OLT.
In summary, total hepatectomy with subsequent transplanta-
tion has the inherent advantage of en bloc resection of not only the
tumour, but indeed the entire liver, addressing any known (or
unknown)multifocal disease.Adherence to strict selection criteria
can achieve excellent results in selected patients. However, recur-
rence continues to be a significant problem after LT, and identifi-
cation of predictive factors could prove valuable for developing
therapeutic strategies.We have found that MVI is a strong predic-
tor of tumour recurrence and thus of patient survival in our
patient population. As the extent of invasion is often determined
retrospectively, tumour size and AFP can be considered the best
surrogates for vascular invasion and possible indicators of more
aggressive lesions. This in part validates the utilization of the
current criteria (e.g. Milan and UCSF) wherein tumour size and
number of lesion are used to select candidates for LT.Nevertheless,
we were unable to demonstrate that the number of lesions was
associated with poor outcomes or a more aggressive type of
cancer. The value of bridging therapy, such as chemoembolization
or ablation, in conjunction with LT and adjuvant therapy to
prevent tumour recurrence and improve patient survival remains
uncertain. Further evaluation of these methods in large prospec-
tive series should be undertaken.
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